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Abstract
Background and Purpose—Apolipoprotein E genotype (APOE) is associated with cholesterol
metabolism, ischemic heart disease, and cerebral amyloid angiopathy, and so may affect risk of
both ischemic and hemorrhagic stroke.
Methods—We comprehensively sought and identified studies of the association of apoE with
ischemic stroke (IS), intracerebral hemorrhage (ICH), and subarachnoid hemorrhage (SAH). We
did meta-analyses to assess the evidence for an association between APOE and the various
pathological types and subtypes of stroke, and assessed the effects of several methodological
criteria.
Results—We analyzed data from 31 eligible studies (26 IS, 8 ICH, and 3 SAH) in 5961 cases
and 17 965 controls. ∊4 allele-containing (∊4+) genotypes were significantly associated with IS
(odds ratio [OR], 1.11; 95% CI, 1.01 to 1.22) and SAH (OR, 1.42; 95% CI, 1.01 to 1.99) and
nonsignificantly with ICH (OR, 1.16; 95% CI, 0.93 to 1.44), whereas ∊2+ genotypes were
associated with ICH (OR, 1.32; 95% CI, 1.01 to 1.74). Associations appeared stronger with ∊4+
genotypes for large artery compared with other IS subtypes and for Asian compared with white
populations, and with ∊2+ genotypes for lobar compared with deep hemorrhages. However, we
found no association between ∊4+ genotypes and IS when we analyzed only larger studies (>200
cases; OR, 0.99; 95% CI, 0.88 to 1.11) or studies without control selection bias (OR, 0.99; 95%
CI, 0.85 to 1.17).
Conclusions—Publication and selection biases make existing studies of APOE and stroke
unreliable. Further, very large, methodologically rigorous studies are needed.
Keywords
apolipoproteins E; genetics; meta-analysis; stroke
Twin and family history studies suggest a genetic component to the risk of all 3 main
pathological types of stroke (ischemic stroke [IS], intracerebral hemorrhage [ICH], and
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subarachnoid hemorrhage [SAH]).1-4 Genes influencing stroke risk may act through the
modification of known risk factors (such as hypertension)5,6 or through novel pathways.
Studies investigating genetic risk factors for human stroke have generally taken a candidate
gene case-control approach, studying polymorphisms, the functional consequences of which
make them likely to influence stroke risk.7,8 Because stroke is complex and pathologically
heterogeneous, there are a large number of potential candidate genes (eg, those involved in
coagulation, cholesterol metabolism, and blood pressure regulation).7,8 The relative risk
associated with any candidate gene is therefore likely to be small, probably not >1.5 at most,
meaning that candidate gene studies in stroke, as for ischemic heart disease, need several
thousand cases and controls to be able to identify reliably any real associations.9,10
Studying several candidate genes or comparing genetic influences between stroke subtypes
or other subgroups needs even larger numbers.11 Many candidate gene studies in stroke
have been completed, but they have generally been too small to reach reliable conclusions,
and many have had other methodological shortcomings, for example, in the selection of an
appropriate control group.7,8,12
The apolipoprotein E gene (apoE for protein, APOE for gene) is one of the most widely
studied genes in vascular and neurodegenerative diseases.13 Its protein product, apoE, is a
glycoprotein with 3 common isoforms, E2, E3, and E4, encoded by the alleles ∊2, ∊3, and
∊4, giving rise to 6 genotypes, with the genotype ∊3/∊3 occurring in about one half to two
thirds of people in most populations. The protein plays a major role in lipid transport and
metabolism and is also significantly expressed in brain.
Compared with ∊3/∊3, ∊4 allele-containing (∊4+) genotypes are associated with increased
total cholesterol levels, whereas ∊2 allele-containing (∊2+) genotypes are associated with
decreased levels.13 This may partly explain why ∊4 carriers have an increased risk of
ischemic heart disease and the observed association in some studies with markers of
atherosclerosis (eg, carotid intima-media thickness).14,15 These associations might suggest
that ∊4 carriers should be at increased risk of IS, particularly large artery atherothrombotic
stroke. However, studies of APOE and IS have produced conflicting results.7,8,16
Studies of cerebral vascular pathology in human brain autopsy and biopsy specimens have
suggested that APOE influences cerebral amyloid angiopathy, which is thought to account
for a substantial proportion of lobar ICHs in the elderly. It appears that although the ∊4
allele enhances amyloid deposition in blood vessels, the ∊2 allele predisposes to
vasculopathic changes leading to rupture of amyloid laden vessels.17,18 Thus, one might
expect ∊4 and ∊2 carriers to have increased susceptibility to ICH, especially in a lobar
location.
A few studies have published data on APOE and SAH. Although variation in susceptibility
to vasculopathic changes could conceivably explain an association, we are not aware of any
evidence for this.
In this article, we use systematic review and meta-analysis methods to assess the potential
association between APOE and the various pathological types and subtypes of stroke.
Methods
Study Identification and Inclusion/Exclusion Criteria
We sought all available published studies in which the association between APOE and
clinically evident (ie, not diagnosed on brain imaging or autopsy only) IS, ICH, or SAH had
been studied in adult humans. We used a detailed electronic search strategy in Medline and
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Embase from 1966 to the end of October 2004, including a combination of MeSH terms and
text words for apoE and for stroke and its subtypes (see Appendix), checked the reference
lists of all relevant studies and review articles thus identified, and also checked the relevant
chapters of recently published textbooks on stroke or stroke genetics.
We excluded studies in which all types of stroke were studied together with no distinction
between different pathological types. We also excluded studies of recurrent stroke in
patients with a previous stroke, or of stroke in patients with serious disease. We initially
sought both full articles and abstracts in all languages, but later excluded studies published
in abstract form only and several studies in non-English languages for which translations
were not readily available because these were all very small and their inclusion would not
have materially affected our conclusions (see Results). For each of the 3 main pathological
types of stroke (IS, ICH, and SAH), 2 authors independently selected studies fulfilling our
inclusion criteria, resolving disagreements by discussion.
Data Extraction
For each study selected, we extracted information on: year of publication; study design (eg,
case control, case cohort, cross-sectional); country in which the study was conducted;
ethnicity of the subjects studied; the number, source, and definitions of the cases and
controls; case-control matching variables, if any; mean age and percentage male among
cases and controls; reported presence of Hardy-Weinberg equilibrium among cases and
controls; whether genotyping staff were blind to case-control status; the types of samples
genotyped and genotyping method used; and availability of genotype or allele frequency
data for subtypes of IS or ICH. We also extracted data on the numbers of cases and controls
with each of the 6 APOE genotypes, allowing calculation of numbers with ∊4 allele-
containing and ∊2 allele-containing genotypes as well as of ∊4 and ∊2 allele frequencies
among case and control chromosomes. For a few studies, we were only able to extract data
on allele frequencies.
For studies with >1 publication describing results among the same or overlapping groups of
patients or controls, we included only the largest of the available published data sets to avoid
double counting. For studies with >1 control group, we used the most appropriate control
group according to the methodological criteria outlined below, and where neither control
group was methodologically superior, we used the largest.
At least 2 authors extracted the above information from each study, resolving any
disagreements by discussion.
Statistical Analyses
We used Cochrane RevMan (version 4.2) software.19 For each study, we calculated an
unadjusted ratio of the odds of being a case to the odds of being a control given an ∊4+
genotype, and given an ∊2+ genotype. For each study, we also extracted information (where
available) on the corresponding adjusted odds ratio (OR) that took account of any matching
or other potential confounding variables. We calculated pooled ORs from the unadjusted
data using the Mantel-Haenszel method.20
We did several prespecified subgroup analyses. For IS, we assessed the effects on the results
of ethnicity and of different IS subtypes, and for ICH we assessed the effects of lobar versus
deep hemorrhage locations. For IS, where the total number of studies and subjects was large,
we also assessed the effects of several methodological quality criteria: the potential for small
study bias (particularly publication bias), comparing results for studies with ≥200 cases
versus those with <200 cases; the quality of selection of the controls, comparing results for
studies in which controls were selected concurrently and without potential bias from the
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same population as the cases (so that if a control in the study had had a stroke they would
have been a case) versus those in which they were not (or where insufficient information
was given); blinding of genotyping staff; and genotyping method.
For our primary analyses, we used the fixed-effects method of meta-analysis, but we also
checked the effects of repeating all analyses using a random-effects model. Our primary
analyses were based on genotypes, avoiding the need to assume presence of Hardy-
Weinberg equilibrium in cases and controls, but we also did analyses comparing ∊4 and ∊2
allele frequencies between case and control chromosomes.
Results
From 866 articles identified, we selected 42 potentially relevant studies after perusal of all
titles, abstracts and, where necessary, full articles.2,17,w1-w44 After exclusions, we were left
with a total of 31 studies in 5961 cases and 17 965 controls (Figure 1).
APOE and IS
We included 26 studies (5018 cases and 16 921 controls; see Figure 1 and details of study
characteristics in the supplemental Table I, available online at http://stroke.ahajournals.org).
The studies were conducted in several European countries, the United States, Brazil,
Taiwan, China, Japan, Korea, and Bangladesh, and included populations of varying
ethnicity. Most used a retrospective case-control design, but a few identified cases and
controls within a cohort. The studies were generally small (mean number of cases 193; only
11 included >200 cases, and none included >1000 cases). Only 4 (1 retrospective case-
control study, and 3 conducted within cohorts) described the selection of the controls
according to our methodological ideal (see above).w7,w13,w15,w18 Although several studies
matched controls to cases on age, sex, and occasionally other variables, and most collected
information on potentially confounding stroke risk factors, only a few performed an
appropriate analysis accounting for these variables.w2,w4,w7,w11,w12,w15,w16,w18,w24 Only 10
studies checked for and reported on Hardy-Weinberg
equilibrium,w6,w9,w13-15,w18,w20,w21,w23,w25,w26 and only 7 mentioned blinding of
genotyping staff.w10,w11,w13,w15,w20,w21,w26,w27 Most carried out genotyping on blood
samples, using polymerase chain reaction (PCR) and restriction enzyme digestion methods,
whereas a few used the Taqman fluorescent detection system and several assigned APOE
genotypes from apoE phenotypes, obtained by isoelectric focusing and immunoblotting.
Two studies provided data on allele frequencies but not genotypes.w6,w20,w21 Only 7 studies
provided data on genotypes for ≥1 etiological subtypes of IS (large artery IS, small artery or
lacunar IS, cardioembolic stroke, and others; Figure 1; supplemental Table
I).w1,w5,w12,w16,w17,w22,w24
Figure 2 shows ORs for ∊4+ versus ∊4- genotypes for the 24 studies with genotype data,
separately and overall. The pooled OR suggested a slight excess risk of IS for ∊4+ genotypes
(OR, 1.11; 95% CI, 1.01 to 1.22) but with marginal statistical significance (P=0.03), a wide
CI, and substantial heterogeneity between the results of the studies (χ223df=75.4;
P<0.00001). When we looked separately at the different IS subtypes in the 7 studies with
available data, there appeared to be a stronger (albeit not independently significant)
relationship between ∊4+ genotypes and large artery ISs (OR, 1.33; 95% CI, 0.99 to 1.78),
with no clear evidence of an association with small artery (lacunar), cardioembolic, or other/
unknown IS subtypes (Figure 3). Analyses by ethnic group suggested a stronger relationship
between ∊4+ genotypes and IS in the various Asian populations than in whites or others,
with marginally significant heterogeneity between the ethnic groups (Figure 3). However,
when we restricted analyses to larger studies with ≥200 cases (which are less prone to small
study biases, especially publication bias) or to studies with unbiased, methodologically
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“ideal” control groups, the modest overall association between ∊4+ genotypes and IS
disappeared (OR larger studies, 0.99, 95% CI, 0.88 to 1.11; OR “ideal” controls, 0.99, 95%
CI, 0.85 to 1.17; Figure 3). Blinding of genotyping staff and the genotyping method used
appeared not to influence the results much (Figure 3). The effect of study size also
influenced the ethnicity subgroup results because the presence of an effect of ∊4+ genotypes
on IS in Asian ethnic groups was only present in the studies with <200 cases (OR smaller
studies, 2.17, 95%, CI 1.56 to 3.03; OR larger studies, 1.09, 95% CI, 0.88 to 1.35;
heterogeneity between 2 groups of studies χ21df=11.6; P=0.0007). We found no overall
association between ∊2+ genotypes and IS (OR, 0.99; 95% CI, 0.87 to 1.13).
Only a few studies reported both unadjusted and appropriately adjusted ORs, but of those
that did, there was generally little difference between the 2 results,w7,w11,w12,w15,w16,w18,w25
suggesting that our meta-analysis of data that did not account for matching or take account
of potential confounders was reasonable.
APOE and ICH
Eight studies (706 cases and 2526 controls) were included (see Figure 1 and details in the
supplemental Table I). 2,17,w6,w12,w13,w16,w28-w33 They were conducted in the United
Kingdom, Portugal, the United States, Japan, and Bangladesh. All used a retrospective case-
control design, and only 1 described selecting controls according to our methodological
ideal.w13 The studies were mainly conducted in single centers and so were small, with the
number of cases ranging from 38 to 188. Four matched cases and controls on age and sex, 4
checked for and reported on Hardy-Weinberg equilibrium, 3 mentioned blinding of
genotyping staff, and all used PCR and restriction enzyme digestion methods for genotyping
(supplemental Table I). Two studies provided data on allele frequencies but not genotypes.
17,w6,w28,w29 Four studies provided data separately for lobar and deep ICHs but 1 of these
provided allele frequency data only.2,17,w28-w32
There was a marginally significant increased odds of ICH among those with an ∊2+
genotype (OR, 1.32; 95% CI, 1.01 to 1.74; Figure 4a). Analyses by hemorrhage location
suggested a stronger relationship for lobar than for deep hemorrhage (Figure 4b). There was
a nonsignificant trend toward increased odds of ICH among those with an ∊4+ genotype
(OR, 1.16; 95% CI, 0.93 to 1.44; Figure 5a), and the suggestion of a stronger (but still
nonsignificant) relationship for lobar than for deep hemorrhage (Figure 5b). For 2 studies,
we were able to compare unadjusted ORs with appropriately adjusted ORs accounting for
matching and potentially confounding variables and found these to be very similar.2,w12
APOE and SAH
Three studies (237 cases and 1655 controls) were included (Figure 1; supplemental Table
I).w12,w31,w33 Pooled analyses showed marginally significant increased odds of SAH in ∊4
carriers (OR, 1.42; 95% CI, 1.01 to 1.99) but no association with ∊2+ genotypes (OR, 1.14;
95% CI, 0.75 to 1.76).
For all of our analyses, random-effects and allele frequency-based analyses generated
similar results (data not shown).
Discussion
The relationship between APOE and IS has been studied in large numbers of subjects in
case-control studies, but the individual studies were generally small and had a variety of
other methodological limitations. In our systematic review, overall pooled results suggested
an association between ∊4+ genotypes and IS, particularly in large artery IS and in Asians,
but analyses of methodological quality criteria showed that these results could have arisen
Sudlow et al. Page 5
Stroke. Author manuscript; available in PMC 2008 November 03.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
from small study and control selection biases. The association between ∊4+ genotypes and
IS disappeared when we considered only the larger (≥200 cases) studies or only the few
studies with “ideal,” unbiased selection of controls (although the heterogeneity between
studies with “ideal” and “nonideal” controls was not statistically significant at conventional
levels). The most important small study bias is probably publication bias (ie, the results of
small negative studies are far less likely to be published than those of small positive studies).
21 Other methodological characteristics of the studies (such as blinding of genotyping staff
and genotyping method) seemed to have less influence on whether or not an association was
detected. Thus, despite evidence of a moderate-sized association between ∊4+ genotypes
and ischemic heart disease (OR, ≈1.3),14 there is currently no convincing evidence for an
association with IS. An association, particularly with large artery IS, remains possible, but
the small numbers of studies and subjects with information on ischemic subtypes and other
methodological limitations preclude firm conclusions.
Our overall results for ICH showed a significant association with ∊2+ genotypes (or the ∊2
allele), a trend toward an association with ∊4+ genotypes (or the ∊4 allele), and a
strengthening of these associations for lobar hemorrhages. This would appear to support the
findings of studies of cerebral amyloid angiopathy, but all of the ICH studies were small,
control group selection was generally of doubtful quality, and reporting bias may have
affected the results for lobar versus deep hemorrhage because they were based on 3 of the 4
most positive studies. The results are therefore no more than suggestive.
Despite no published theoretical basis for an association between APOE and SAH, we found
a just statistically significant association with ∊4+ genotypes in our meta-analysis. However,
this was based on only small numbers of cases and controls, and seems far more likely to be
the combined result of publication and reporting bias than to reflect a true underlying
association.
None of the studies in our systematic review even approached fulfilling a set of recently
suggested methodological quality criteria for genetic association studies in stroke.12 Similar
methodological problems are likely to affect existing studies of other candidate genes in
stroke. Reliable answers for APOE and other candidate genes will only come from studies
an order of magnitude larger than those performed to date (ie, with thousands of cases and
controls), with appropriate selection of controls and standardized methods for defining
subtypes of ischemic and hemorrhagic stroke. This is only likely to be achieved with a
multicenter collaborative approach. In the future, statistical methods using marker genotype
data may allow the detection and control of confounding attributable to population
stratification and selection bias in genetic association studies,22 so avoiding the need for
“ideal” control groups, but such methods have not yet been successfully applied in stroke.
Case-control studies that are nested within population-based cohort studies are far less prone
to control selection bias but need to be extremely large with long follow-up for enough cases
to accrue. For example, the UK Biobank study plans to recruit and follow up half a million
middle-aged adults. Projections suggest that it will take 5 years for just 1000 stroke cases to
occur, suggesting that pooling of data with other similar studies will be necessary to achieve
the required sample size for stroke.23 Furthermore, the full potential of such studies will
rely on the adequate identification of stroke cases and classification of pathological types
and subtypes.12
Addendum
After we completed our systematic review, we have become aware of 2 further relevant
studies. In 1, a 3-fold increased odds of previously symptomatic cerebral infarction was
found with APOE ∊4+ genotypes in an autopsy study (33 cases and 181 controls).w45 In
another, a 2-fold increased odds of lobar ICH was found with APOE ∊4+ but not ∊2+
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genotypes (107 cases and 205 controls, of whom 67 cases and 131 controls were in a
previous report, the results of which were included in our systematic review).w46
Incorporating the small amounts of additional data from these studies into our meta-analyses
would not materially affect our results or conclusions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Appendix
Search Strategy in Medline*
1. apolipoproteins/ or apolipoproteins e/
2. ((apolipoprotein$ adj e) or (apoprotein$ adj e) or apo-e or apo e or apoe).tw.
3. ((apolipoprotein$ adj e2) or (apoprotein$ adj e2) or apo-e2 or apo e2 or apoe2).tw.
4. ((apolipoprotein$ adj e3) or (apoprotein$ adj e3) or apo-e3 or apo e3 or apoe3).tw.
5. ((apolipoprotein$ adj e4) or (apoprotein$ adj e4) or apo-e4 or apo e4 or apoe4).tw.
6. ((apolipoprotein$ adj e5) or (apoprotein$ adj e5) or apo-e5 or apo e5 or apoe5).tw.
7. ((apolipoprotein$ adj e7) or (apoprotein$ adj e7) or apo-e7 or apo e7 or apoe7).tw.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. exp cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or exp
brain ischemia/ or exp carotid artery diseases/ or exp cerebrovascular accident/ or
exp hypoxia-ischemia, brain/ or exp intracranial arterial diseases/ or exp
“intracranial embolism and thrombosis”/ or exp intracranial hemorrhages/ or
vasospasm, intracranial/
10. (stroke$ or apoplexy or cerebral vasc$ or cerebrovasc$ or cva$).tw
11. 9 or 10
12. 8 and 11
13. limit 12 to human
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Figure 1.
Flow chart illustrating numbers of studies (and cases and controls) included in the meta-
analyses.
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Figure 2.
Meta-analysis of case-control studies of effects of APOE ∊4+ genotype on IS. Studies are
shown in order of publication date, the earliest first. The OR for each study is shown as a
square, the area of which is proportional to its variance, so that larger studies have larger
squares. Horizontal lines denote 95% CIs. The summary OR is shown as a diamond, the
width of which represents its 95% CI.
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Figure 3.
Meta-analysis of case-control studies of effects of APOE ∊4+ genotype on IS-pooled results
for various subgroups. The OR for each subgroup is shown as a square for which the area is
proportional to its variance, so that larger studies have larger squares. Horizontal lines
denote 95% CIs. Formal heterogeneity between IS subtypes was not calculable because of
double counting of control groups. *Heterogeneity between 3 groups: χ22df=5.6; P=0.06.
†Heterogeneity between 2 groups: χ21df=12.0; P=0.0005. ‡Heterogeneity between 2
groups: χ21df=2.9; P=0.09. ¶Heterogeneity between 2 groups: χ21df=1.5; P=0.2.
§Heterogeneity between 3 groups: χ22df=0.1; P=0.9.
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Figure 4.
a, Meta-analysis of case-control studies of effects of APOE ∊2+ genotype on ICH. Notation
as for Figure 2. Heterogeneity between 6 studies: χ25df=9.3; P=0.1. b, Meta-analysis of
case-control studies of effects of APOE ∊2+ genotype on ICH subdivided by location (lobar
and deep). The summary OR for each location is shown as a diamond, the width of which
represents its 95% CI. Formal heterogeneity between hemorrhage locations not calculable
because of double counting of control groups.
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Figure 5.
a, Meta-analysis of case-control studies of effects of APOE ∊4+ genotype on ICH. Notation
as for Figure 2. Heterogeneity between 6 studies: χ25df=1.9; P=0.9. b, Metaanalysis of
case-control studies of effects of APOE ∊4+ genotype on ICH subdivided by location (lobar
and deep). Notation as for Figure 4b.
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